Skip to main content

Table 1 Demography and clinical characteristics of patients (n = 8)

From: A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

Characteristics Number Percent
Age  
 Median (range) 49.2 (35.7–71.8)
Histology Type   
 Invasive Ductal Carcinoma 8 100
Hormone Receptor Status   
 ER- and PR- 3 37.5
 ER- and PR+ 4 50.0
 ER+ and PR- 0 0
 ER+ and PR+ 1 12.5
HER2 Expression   
 IHC 0-2+ and/or FISH - 3 37.5
 IHC 2+ and FISH +, IHC 3+ 5 62.5
Hormonal and HER2 Status   
 Triple Negative 0 0.0
 ER+ and HER2- 3 37.5
 HER2+ 5 62.5
Molecular Subtype   
 Luminal A 3 37.5
 Luminal B 1 12.5
 HER2+/ER- 4 50.0
 Basal-like 0 0.0
ECOG Performance Status   
 0-1 4 50.0
 2 3 37.5
 3 1 12.5
  1. Note: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluorescent in situ hybridization, ECOG Eastern Cooperative Oncology Group